welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Development of Late-Stage CPP-1X/Sulindac Combination for Familial Adenomatous Polyposis
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America. This product is currently in a Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP).
expertly curated content related to this topic
-
Bon Voyage: Traveling with a J-Pouch Part 1https://www.youtube.com/watch?v=NlhsEEuo...
-
Surgical Treatment of Familial Adenomatous Polyposis: Dilemmas and Current RecommendationsFamilial adenomatous polyposis (FAP) is ...
-
Inherited Cancer Syndromes: Current Clinical ManagementElectronic Book: The second edition of I...
-
Kasia J. Bloch, BS, BA, MS, LGCGenetic Counselor Education: MS, Gene...
-
HELIOS Klinikum WuppertalCenter for Hereditary Tumor Di...
-
Desmoid Clinical Trial Update & Stuff!https://www.youtube.com/watch?v=uaMKoMHE...
-
Massachusetts General Hospital Cancer CenterThe Gastrointestinal Cancer Genetics Pro...